My research has focused on the development of novel statistical and bioinformatic methodologies that facilitate the study of translational research questions in cancer genomics and immuno-oncology. I developed several algorithms including iCluster and FACETS that are widely used in research community.
Peng X, Lee J, Adamow M, Maher C, Postow MA, Callahan MK, Panageas KS, Shen R*. A topic modeling approach reveals the dynamic T cell composition of peripheral blood during cancer immunotherapy. Cell Reports Methods. 2023
Shen R, Postow MA, Adamow M, Arora A, Hannum M, Maher C, Wong P, Curran MA, Hollmann TJ, Jia L, Al-Ahmadie H, et al. LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science translational medicine. 2021
Chakraborty S, Martin A, Guan Z, Begg C, Shen R*. Mining mutation contexts across the cancer genome to map tumor site of origin. Nat Communications. 2021
Shen R and Seshan V. (2016) FACETS: allele-specific copy number estimates from tumor sequencing. Nucleic Acids Res. 2016
Mo Q, Wang S, Seshan VE, Olshen AB, Schultz N, Sander C, Powers RS, Ladanyi M, and Shen R*. Pattern discovery and cancer gene identification in integrated cancer genomic data. Proc Natl Acad Sci U S A. 2013
My research has focused on the development of novel statistical and bioinformatic methodologies that facilitate the study of translational research questions in cancer genomics and immuno-oncology.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Ronglai Shen discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].